Valuations could get investors, acquirers hunting for opportunities

Beaten down valuations and a large swath of new companies has investors optimistic there are plenty of buying opportunities heading into 2022, whether for themselves or potential acquirers. But the flood of new companies coming to market is expected to slow as poor IPO performance translates to less crossover activity.

A year of dramatic underperformance by biotech has one silver lining for investors: it has set up 2022 with many names looking very attractive from a valuation perspective, as a large portion of stocks are near 52-week lows...